News | November 05, 2006

Barnes-Jewish Hospital Poised for CardioWest Implantation

Washington University surgeons at Barnes-Jewish Hospital, St. Louis, began training at UMC in Tucson on Nov. 2 to become one of only nine hospitals in the U.S. certified to implant the CardioWest temporary Total Artificial Heart (TAH-t). Ranked No. 10 on the “U.S. News and World Report’s” Best Heart Hospitals of 2006, the Barnes-Jewish program has earned a reputation for taking on the most challenging cases, including patients who may have been turned down at other implant centers.

The heart transplant team, led by Dr. Nader Moazami, will be the first in the St. Louis area to be certified to implant the TAH-t, a modern version of the Jarvik-7 Artificial Heart.

The program is known as one of the leading centers in the country for post-transplant care and use of cardiac assist devices.

“We know that it (TAH-t) salvages a large number of patients who are really spiraling downward so rapidly that there’s no other device that can bring them back and this device (the TAH-t) does it,” said Dr. Jack Copeland, who has been a leader in artificial heart surgery since 1985.
The CardioWest TAH-t replaces the patient's dying heart. In most patients it is able to restore cardiac output. This facilitates recovery of vital organs, such as the liver and kidneys that have declined because of low blood flow. This improves the condition of patients who were near death from end stage biventricular heart failure. The TAH-t makes them better able to survive a heart transplant.”

Related Content

Effect of Daily Aspirin on First-Time Heart Attack and Stroke Risk Inconclusive
News | Pharmaceuticals | September 04, 2018
The jury is still out on whether people at moderate risk of a first heart attack or stroke should take daily aspirin to...
Blood Pressure and Cholesterol-lowering Drugs Continue to Improve Survival After a Decade
News | Pharmaceuticals | August 27, 2018
Blood pressure and cholesterol-lowering drugs continue to improve survival in patients with hypertension after more...
Pfizer Announces Positive Topline Results from Phase 3 ATTR-ACT Study
News | Pharmaceuticals | April 06, 2018
Pfizer Inc. announced that the Tafamidis Phase 3 Transthyretin Cardiomyopathy (ATTR-ACT) study met its primary endpoint...
Humanetics Presents Data on Drug to Protect Cardiac Cells From Space-Like Radiation

Photo from NASA

News | Pharmaceuticals | February 01, 2018
February 1, 2018 –Humanetics Corporation (Humanetics) has recently completed two research studies funded by the Natio
Xarelto Significantly Reduces Major Cardioavascular Events in Stable CAD and PAD Patients
News | Pharmaceuticals | October 18, 2017
October 18, 2017 — Results from the pivotal Phase 3 COMPASS study found that the...
News | Pharmaceuticals | October 04, 2017
October 4, 2017 — MyoKardia Inc.
News | Pharmaceuticals | September 12, 2017
September 12, 2017 — Inclisiran lowers low-density lipoprotein (LDL, or “bad”) cholesterol for up to one year in pati
Merck Announces Results of REVEAL Outcomes Study of Anacetrapib
News | Pharmaceuticals | September 11, 2017
Merck and researchers in the Clinical Trial Service Unit at the University of Oxford announced the publication and...
Statins Associated With Improved Heart Structure and Function
News | Pharmaceuticals | May 26, 2017
Statins are associated with improved heart structure and function, according to research presented at EuroCMR 2017, May...
Feature | Pharmaceuticals | May 16, 2017
May 16, 2017 – Results of a groundbreaking clinical trial demonstrate the effectiveness of a novel, fast-acting nasal
Overlay Init